8-KEarnings & Results

DEXCOM INC 8-K Report, Financial Results (Jan 13, 2015)

Filed January 13, 2015For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K report on January 13, 2015, to provide preliminary unaudited financial results and business updates. The company announced strong fourth-quarter 2014 product revenues, estimated at approximately $84 million, representing a significant sequential increase of 24% and a year-over-year increase of 64% compared to Q4 2013. For the full fiscal year 2014, DexCom's product revenue was approximately $257 million, a substantial 64% growth from 2013. Furthermore, DexCom reported impressive growth in its patient base, which expanded by over 50% in the United States during fiscal year 2014. Looking ahead, the company provided an optimistic initial product revenue forecast for fiscal year 2015, projecting a range of $340 million to $360 million. These positive preliminary results and guidance indicate strong market adoption and growth for DexCom's diabetes monitoring technologies.

Key Highlights

  • 1Estimated Q4 2014 product revenue of approximately $84 million, a 24% sequential increase and 64% year-over-year increase.
  • 2Full fiscal year 2014 product revenue reached approximately $257 million, a 64% increase from fiscal year 2013.
  • 3U.S. patient base grew by over 50% during fiscal year 2014.
  • 4Provided an initial product revenue guidance for fiscal year 2015 between $340 million and $360 million.
  • 5Results were announced in conjunction with a presentation at the J.P. Morgan 33rd Annual Healthcare Conference.
  • 6The reported financial results are unaudited and subject to finalization.

Frequently Asked Questions

DexCom estimated its product revenue for the fourth quarter of 2014 to be approximately $84 million. This represents a significant increase of about 24% from the previous quarter and a substantial 64% increase compared to the fourth quarter of 2013.

For the full fiscal year 2014, DexCom reported estimated product revenue of approximately $257 million, marking a robust 64% growth compared to fiscal year 2013.

DexCom provided an initial product revenue forecast for fiscal year 2015, projecting a range between $340 million and $360 million, indicating continued expected growth.

In addition to revenue figures, DexCom highlighted that its patient base in the United States experienced growth of more than 50% during fiscal year 2014, demonstrating increasing adoption of their products.